

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
11 August 2005 (11.08.2005)

PCT

(10) International Publication Number
WO 2005/073219 A1

(51) International Patent Classification⁷: **C07D 403/04**,
405/06

(21) International Application Number:
PCT/GB2005/000281

(22) International Filing Date: 27 January 2005 (27.01.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0402140.8 30 January 2004 (30.01.2004) GB

(71) Applicant (for all designated States except US):
SMITHKLINE BEECHAM CORPORATION
[US/US]; One Franklin Plaza, PO Box 7929, Philadelphia,
PA 19101 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CAMPOS, Se-**
bastien, Andre [FR/GB]; GlaxoSmithKline, Gunnels
Wood Road, Stevenage Hertfordshire SG1 2NY (GB).
SWANSON, Stephen [GB/GB]; GlaxoSmithKline, Gun-
nels Wood Road, Stevenage Hertfordshire SG1 2NY (GB).
WALKER, Ann, Louise [GB/GB]; GlaxoSmithKline,
Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY
(GB).

(74) Agent: **GLADWIN, Amanda, Rachel**; GlaxoSmithK-
line, Corporate Intellectual Property, 980 Great West Road,
Brentford Middlesex TW8 9GS (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,

GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii)) for the following designations AE,
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE,
EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA,
ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ,
NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT,
BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR,
HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG)

— as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii)) for the following desig-
nations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW,

[Continued on next page]

(54) Title: FUSED HETEROARYL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS IN THE TREATMENT OF I.A. RHEUMATOID ARTHRITIS



(I)

(57) Abstract: Compounds of formula: (I) are inhibitors of p38 kinase and are useful in the treatment of conditions or disease states mediated by p38 kinase activity or mediated by cytokines produced by the activity of p38.

WO 2005/073219 A1



BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR,

HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— of inventorship (Rule 4.17(iv)) for US only

Published:


— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

FUSED HETEROARYL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS IN THE TREATMENT OF I.A. RHEUMATOID ARTHRITIS

This invention relates to novel compounds and their use as pharmaceuticals, particularly as p38 kinase inhibitors, for the treatment of conditions or disease states mediated by p38 kinase activity or mediated by cytokines produced by the activity of p38 kinase.

We have now found a group of novel compounds that are inhibitors of p38 kinase. According to the invention there is provided a compound of formula (I):



(I)

wherein

A is a fused 5-membered heteroaryl ring substituted by $-(CH_2)_m$ heterocyclyl wherein the heterocyclyl is a 5- or 6-membered heterocyclic ring containing one or two heteroatoms independently selected from oxygen, sulfur and nitrogen optionally substituted by up to two substituents independently selected from oxo, C₁₋₆alkyl, $-(CH_2)_n$ phenyl, -OR³, $-(CH_2)_nCO_2R^3$, -NR³R⁴ and -CONR³R⁴, and

A is optionally further substituted by one substituent selected from -OR³, halogen, trifluoromethyl, -CN, -CO₂R³ and C₁₋₆alkyl optionally substituted by hydroxy;

R¹ is selected from methyl and chloro;

R² is selected from -NH-CO-R⁵ and -CO-NH-(CH₂)_q-R⁶;

R³ and R⁴ are each independently selected from hydrogen and C₁₋₆alkyl;

R⁵ is selected from hydrogen, C₁₋₆alkyl, $-(CH_2)_q$ -C₃₋₇cycloalkyl, trifluoromethyl, $-(CH_2)_r$ heteroaryl optionally substituted by R⁷ and/or R⁸, and $-(CH_2)_r$ phenyl optionally substituted by R⁷ and/or R⁸;

R⁶ is selected from hydrogen, C₁₋₆alkyl, C₃₋₇cycloalkyl, -CONHR⁹, phenyl optionally substituted by R⁷ and/or R⁸, and heteroaryl optionally substituted by R⁷ and/or R⁸;

R⁷ is selected from C₁₋₆alkyl, C₁₋₆alkoxy, $-(CH_2)_q$ -C₃₋₇cycloalkyl, -CONR⁹R¹⁰, -NHCOR¹⁰, halogen, -CN, $-(CH_2)_s$ NR¹¹R¹², trifluoromethyl, phenyl optionally substituted by one or more R⁸ groups, and heteroaryl optionally substituted by one or more R⁸ groups;

R⁸ is selected from C₁₋₆alkyl, C₁₋₆alkoxy, halogen, trifluoromethyl, and $-(CH_2)_s$ NR¹¹R¹²;

R⁹ and R¹⁰ are each independently selected from hydrogen and C₁₋₆alkyl, or

R^9 and R^{10} , together with the nitrogen atom to which they are bound, form a 5- or 6-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N- R^{13} , wherein the ring may be substituted by up to two C_{1-6} alkyl groups;

R^{11} is selected from hydrogen, C_{1-6} alkyl and $-(CH_2)_q-C_{3-7}$ cycloalkyl optionally substituted by C_{1-6} alkyl,

R^{12} is selected from hydrogen and C_{1-6} alkyl, or

R^{11} and R^{12} , together with the nitrogen atom to which they are bound, form a 5- or 6-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N- R^{13} ;

R^{13} is selected from hydrogen and methyl;

X and Y are each independently selected from hydrogen, methyl and halogen;

m and q are each independently selected from 0, 1 and 2;

n and r are each independently selected from 0 and 1; and

s is selected from 0, 1, 2 and 3;

with the proviso that:


A is not substituted by $-(CH_2)_mNR^{14}R^{15}$ wherein R^{14} and R^{15} , together with the nitrogen atom to which they are bound, form a 5- or 6-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulphur and NR^{16} wherein R^{16} is hydrogen or methyl,

when m is 0, the $-(CH_2)_m$ heterocyclyl group is not a 5- or 6-membered heterocyclyl ring containing nitrogen optionally substituted by C_{1-2} alkyl or $-(CH_2)_nCO_2R^3$, and

the compound of formula (I) is not 1,1-dimethylethyl 4-(6-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-1,2-benzisoxazol-3-yl)-1-piperazinecarboxylate;

or a pharmaceutically acceptable derivative thereof.

According to a further embodiment of the invention there is provided a compound of formula (IA):



(IA)

wherein

A is a fused 5-membered heteroaryl ring substituted by $-(CH_2)_m$ heterocyclyl wherein the heterocyclyl is a 5- or 6-membered heterocyclic ring containing one or two heteroatoms independently selected from oxygen, sulfur and nitrogen optionally substituted by up to two substituents independently selected from oxo, C_{1-6} alkyl, $-(CH_2)_n$ phenyl, $-OR^3$, $-(CH_2)_nCO_2R^3$, $-NR^3R^4$ and $-CONR^3R^4$, and

A is optionally further substituted by one substituent selected from $-OR^3$, halogen, trifluoromethyl, $-CN$, $-CO_2R^3$ and C_{1-6} alkyl optionally substituted by hydroxy;

R^1 is selected from methyl and chloro;

R^2 is selected from $-NH-CO-R^5$ and $-CO-NH-(CH_2)_q-R^6$;

R^3 and R^4 are each independently selected from hydrogen and C_{1-6} alkyl;

R^5 is selected from hydrogen, C_{1-6} alkyl, $-(CH_2)_q-C_{3-7}$ cycloalkyl, trifluoromethyl, $-(CH_2)_r$ heteroaryl optionally substituted by R^7 and/or R^8 , and $-(CH_2)_r$ phenyl optionally substituted by R^7 and/or R^8 ;

R^6 is selected from hydrogen, C_{1-6} alkyl, C_{3-7} cycloalkyl, $-CONHR^9$, phenyl optionally substituted by R^7 and/or R^8 , and heteroaryl optionally substituted by R^7 and/or R^8 ;

R^7 is selected from C_{1-6} alkyl, C_{1-6} alkoxy, $-(CH_2)_q-C_{3-7}$ cycloalkyl, $-CONR^9R^{10}$, $-NHCOR^{10}$, halogen, $-CN$, $-(CH_2)_sNR^{11}R^{12}$, trifluoromethyl, phenyl optionally substituted by one or more R^8 groups, and heteroaryl optionally substituted by one or more R^8 groups;

R^8 is selected from C_{1-6} alkyl, C_{1-6} alkoxy, halogen, trifluoromethyl, and $-(CH_2)_sNR^{11}R^{12}$;

R^9 and R^{10} are each independently selected from hydrogen and C_{1-6} alkyl, or

R^9 and R^{10} , together with the nitrogen atom to which they are bound, form a 5- or 6-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and $N-R^{13}$, wherein the ring may be substituted by up to two C_{1-6} alkyl groups;

R^{11} is selected from hydrogen, C_{1-6} alkyl and $-(CH_2)_q-C_{3-7}$ cycloalkyl optionally substituted by C_{1-6} alkyl,

R^{12} is selected from hydrogen and C_{1-6} alkyl, or

R^{11} and R^{12} , together with the nitrogen atom to which they are bound, form a 5- or 6-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and $N-R^{13}$;

R^{13} is selected from hydrogen and methyl;

X and Y are each independently selected from hydrogen, methyl and halogen;

m and q are each independently selected from 0, 1 and 2;

n and r are each independently selected from 0 and 1; and


s is selected from 0, 1, 2 and 3;

with the proviso that when m is 0, the $-(CH_2)_m$ heterocyclyl group is not a 5- or 6-membered heterocyclyl ring containing nitrogen optionally substituted by C_{1-2} alkyl or $-(CH_2)_nCO_2R^3$;


or a pharmaceutically acceptable derivative thereof.

In one embodiment, A includes fused 5-membered heteroaryl rings containing up to two heteroatoms independently selected from oxygen, nitrogen and sulfur. In another embodiment, A includes fused 5-membered heteroaryl rings containing up to two


heteroatoms independently selected from oxygen and nitrogen. In a further embodiment, A includes 5-membered heteroaryl rings containing two heteroatoms independently selected from oxygen and nitrogen, for example rings containing two nitrogen atoms. Examples of suitable A groups include fused isoxazolyl, pyrazolyl, pyrrolyl and thiazolyl rings such as those shown below:




For example, suitable A groups include fused pyrazolyl rings such as those shown below:



A representative example of an A group is a fused pyrazolyl ring such as that shown below:




A further representative example of an A group is a fused pyrazolyl ring such as that shown below:



A representative example of a compound of formula (I) is wherein ring A is substituted by $-(CH_2)_m$ heterocyclyl, located on any position on the ring.

- 5 For example, compounds of formula (I) include compounds wherein ring A is a fused pyrazolyl ring substituted by $-(CH_2)_m$ heterocyclyl in position (i) or (ii), for example position (ii), as shown below:



- 10 In one embodiment, the heterocyclyl is a 5- or 6-membered heterocyclic ring containing one or two heteroatoms independently selected from oxygen and nitrogen. Representative examples of the heterocyclyl include tetrahydrofuranyl, tetrahydropyranyl and morpholiny. Further representative examples of the heterocyclyl include piperidiny and piperazinyl. In a further embodiment, the heterocyclyl is a 5- or 6-membered heterocyclic ring containing one oxygen atom. For example, the heterocyclyl is tetrahydropyran.

The heterocyclyl is optionally substituted and the substituents may be located on any position on the heterocyclyl. For example, when the heterocyclyl contains a sulfur atom, the sulfur atom may have up to two oxo substituents.

- 20 In one embodiment, the heterocyclyl is optionally substituted by one substituent selected from oxo, C_{1-6} alkyl, in particular C_{1-4} alkyl, $-(CH_2)_n$ phenyl, $-OR^3$, $-(CH_2)_nCO_2R^3$, $-NR^3R^4$ and $-CONR^3R^4$. In another embodiment, the heterocyclyl is substituted by one substituent selected from oxo, C_{3-6} alkyl, $-(CH_2)_n$ phenyl, $-OR^3$, $-NR^3R^4$ and $-CONR^3R^4$. In another embodiment, the heterocyclyl is substituted by one substituent selected from oxo, $-(CH_2)_n$ phenyl, $-OR^3$, $-NR^3R^4$ and $-CONR^3R^4$. In a further embodiment, the heterocyclyl is optionally substituted by one substituent selected from $-(CH_2)_n$ phenyl, $-(CH_2)_nCO_2R^3$ and $-CONR^3R^4$. A representative example of a heterocyclyl substituent is $-(CH_2)_n$ phenyl. Further representative examples of a heterocyclyl substituent include $-(CH_2)_nCO_2R^3$ and $-CONR^3R^4$.

A representative example of R^1 is methyl.

- 30 A representative example of R^2 is $-CO-NH-(CH_2)_q-R^6$.

In one embodiment, R^3 and R^4 are independently selected from hydrogen and C_{1-4} alkyl. A representative example of R^3 is C_{1-4} alkyl, for example ethyl or t-butyl. A representative example of R^4 is hydrogen.

In one embodiment, R^5 is $-(CH_2)_r$ heteroaryl optionally substituted by R^7 and/or R^8 .

In one embodiment, R^6 is selected from C_{3-7} cycloalkyl, phenyl optionally substituted by R^7 and/or R^8 , and heteroaryl optionally substituted by R^7 and/or R^8 . In a further embodiment, R^6 is selected from C_{1-6} alkyl and C_{3-7} cycloalkyl. A representative example of R^6 is C_{3-6} cycloalkyl, in particular cyclopropyl. A further representative example of R^6 is C_{1-4} alkyl, in particular ethyl.

In one embodiment, R^7 and R^8 are each independently C_{1-4} alkoxy or $-(CH_2)_sNR^{11}R^{12}$.

In one embodiment, R^9 and R^{10} are each independently hydrogen or C_{1-4} alkyl.

In one embodiment, R^{11} and R^{12} , together with the nitrogen atom to which they are bound, form a 5- or 6-membered heterocyclic ring optionally further containing one additional oxygen atom.

In one embodiment, X and Y are each independently selected from hydrogen, chlorine and fluorine. In a further embodiment, X is selected from hydrogen and fluorine. A representative example of X is fluorine. A further representative example of X is hydrogen. A representative example of Y is hydrogen.

In one embodiment, m is selected from 1 and 2. In a further embodiment, m is selected from 0 and 1. A representative example of m is 1. A further representative example of m is 0.

In one embodiment, when m is 0, the heterocyclyl of $-(CH_2)_m$ heterocyclyl is a 5- or 6-membered heterocyclic ring containing oxygen or sulfur, or containing two heteroatoms independently selected from oxygen, sulfur and nitrogen, optionally substituted by up to two substituents independently selected from oxo, C_{1-6} alkyl, $-(CH_2)_n$ phenyl, $-OR^3$, $-(CH_2)_nCO_2R^3$, $-NR^3R^4$ and $-CONR^3R^4$, the heterocyclyl of $-(CH_2)_m$ heterocyclyl is a 5- or 6-membered heterocyclic ring containing nitrogen substituted by one or two substituents independently selected from oxo, C_{3-6} alkyl, $-(CH_2)_n$ phenyl, $-OR^3$, $-NR^3R^4$ and $-CONR^3R^4$, or the heterocyclyl of $-(CH_2)_m$ heterocyclyl is a 5- or 6-membered heterocyclic ring containing nitrogen substituted by two substituents independently selected from C_{1-2} alkyl and $-(CH_2)_nCO_2R^3$, and

when m is 1 or 2, the heterocyclyl of $-(CH_2)_m$ heterocyclyl is a 5- or 6-membered heterocyclic ring containing one or two heteroatoms independently selected from oxygen, sulfur and nitrogen optionally substituted by up to two substituents independently selected from oxo, C_{1-6} alkyl, $-(CH_2)_n$ phenyl, $-OR^3$, $-(CH_2)_nCO_2R^3$, $-NR^3R^4$ and $-CONR^3R^4$.

In a further embodiment, when m is 0, the heterocyclyl of $-(CH_2)_m$ heterocyclyl is a 5- or 6-membered heterocyclic ring containing oxygen or sulfur, or containing two heteroatoms independently selected from oxygen, sulfur and nitrogen, optionally substituted by up to two substituents independently selected from oxo, C_{1-6} alkyl, $-(CH_2)_n$ phenyl, $-OR^3$, $-NR^3R^4$ and $-CONR^3R^4$, the heterocyclyl of $-(CH_2)_m$ heterocyclyl is a 5- or 6-membered heterocyclic ring containing nitrogen substituted by one or two substituents independently selected from oxo,

C₃₋₆alkyl, -(CH₂)_nphenyl, -OR³, -NR³R⁴ and -CONR³R⁴, or the heterocyclyl of -(CH₂)_mheterocyclyl is a 5- or 6-membered heterocyclic ring containing nitrogen substituted by two substituents independently selected from C₁₋₂alkyl and -(CH₂)_nCO₂R³, and

when m is 1 or 2, the heterocyclyl of -(CH₂)_mheterocyclyl is a 5- or 6-membered heterocyclic ring containing one or two heteroatoms independently selected from oxygen, sulfur and nitrogen optionally substituted by up to two substituents independently selected from oxo, C₁₋₆alkyl, -(CH₂)_nphenyl, -OR³, -(CH₂)_nCO₂R³, -NR³R⁴ and -CONR³R⁴.

A representative example of n is 1. A further representative example of n is 0.

A representative example of q is 0.

In one embodiment, r is 0.

In one embodiment, s is 0.

It is to be understood that the present invention covers all combinations of the embodiments and the particular and preferred groups described hereinabove. It is also to be understood that the present invention encompasses compounds of formula (I) in which a particular group or parameter, for example R³, R⁴, R⁸, R¹¹, R¹², R¹³, n, q or s, may occur more than once. In such compounds it will be appreciated that each group or parameter is independently selected from the values listed.

Particular compounds according to the invention include those mentioned in the Examples and their pharmaceutically acceptable derivatives, for example *N*-cyclopropyl-3-fluoro-4-methyl-5-[1-(tetrahydro-2*H*-pyran-2-ylmethyl)-1*H*-indazol-5-yl]benzamide and pharmaceutically acceptable derivatives thereof.

As used herein, the term "pharmaceutically acceptable" means a compound which is suitable for pharmaceutical use. Salts and solvates of compounds of the invention which are suitable for use in medicine are those wherein the counterion or associated solvent is pharmaceutically acceptable. However, salts and solvates having non-pharmaceutically acceptable counterions or associated solvents are within the scope of the present invention, for example, for use as intermediates in the preparation of other compounds of the invention and their pharmaceutically acceptable salts and solvates.

As used herein, the term "pharmaceutically acceptable derivative", means any pharmaceutically acceptable salt, solvate or prodrug, e.g. ester, of a compound of the invention, which upon administration to the recipient is capable of providing (directly or indirectly) a compound of the invention, or an active metabolite or residue thereof. Such derivatives are recognizable to those skilled in the art, without undue experimentation. Nevertheless, reference is made to the teaching of Burger's Medicinal Chemistry and Drug Discovery, 5th Edition, Vol 1: Principles and Practice, which is incorporated herein by reference to the extent of teaching such derivatives. Preferred pharmaceutically acceptable derivatives are salts, solvates, esters, carbamates and phosphate esters. Particularly preferred pharmaceutically acceptable derivatives are salts, solvates and esters. Most preferred pharmaceutically acceptable derivatives are salts and esters, in particular salts.

The compounds of the present invention may be in the form of and/or may be administered as a pharmaceutically acceptable salt. For a review on suitable salts see Berge *et al.*, J. Pharm. Sci., 1977, 66, 1-19.

Typically, a pharmaceutical acceptable salt may be readily prepared by using a desired acid or base as appropriate. The salt may precipitate from solution and be collected by filtration or may be recovered by evaporation of the solvent.

Salts of the compounds of the present invention may, for example, comprise acid addition salts resulting from reaction of an acid with a nitrogen atom present in a compound of formula (I). Salts encompassed within the term "pharmaceutically acceptable salts" refer to non-toxic salts of the compounds of this invention. Suitable addition salts are formed from acids which form non-toxic salts and examples are acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium edetate, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, ethanesulfonate, formate, fumarate, gluceptate, gluconate, glutamate, glycolylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydrogen phosphate, hydroiodide, hydroxynaphthoate, iodide, isethionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, monopotassium maleate, mucate, napsylate, nitrate, N-methylglucamine, oxalate, oxaloacetate, pamoate (embonate), palmitate, pantothenate, phosphate/diphosphate, piruvate, polygalacturonate, saccharate, salicylate, stearate, subacetate, succinate, sulfate, tannate, tartrate, teoclate, tosylate, triethiodide, trifluoroacetate and valerate.

Pharmaceutically acceptable base salts include ammonium salts such as a trimethylammonium salt, alkali metal salts such as those of sodium and potassium, alkaline earth metal salts such as those of calcium and magnesium and salts with organic bases, including salts of primary, secondary and tertiary amines, such as isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexyl amine and N-methyl-D-glucamine.

Those skilled in the art of organic chemistry will appreciate that many organic compounds can form complexes with solvents in which they are reacted or from which they are precipitated or crystallized. These complexes are known as "solvates". As used herein, the term "solvate" refers to a complex of variable stoichiometry formed by a solute (in this invention, a compound of formula (I) or a salt thereof) and a solvent. Such solvents for the purpose of the invention may not interfere with the biological activity of the solute. Examples of suitable solvents include water, methanol, ethanol and acetic acid. Preferably the solvent used is a pharmaceutically acceptable solvent. Examples of suitable pharmaceutically acceptable solvents include water, ethanol and acetic acid. Most preferably the solvent used is water. A complex with water is known as a "hydrate". Solvates of the compounds of the invention are within the scope of the invention.

As used herein, the term "prodrug" means a compound which is converted within the body, e.g. by hydrolysis in the blood, into its active form that has medical effects. Pharmaceutically acceptable prodrugs are described in T. Higuchi and V. Stella, Prodrugs as Novel Delivery Systems, Vol. 14 of the A.C.S. Symposium Series; Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987; and in D. Fleisher, S. Ramon and H. Barbra "Improved oral drug delivery:

solubility limitations overcome by the use of prodrugs", Advanced Drug Delivery Reviews (1996) 19(2) 115-130, each of which are incorporated herein by reference.

Prodrugs are any covalently bonded carriers that release a compound of formula (I) *in vivo* when such prodrug is administered to a patient. Prodrugs are generally prepared by modifying functional groups in a way such that the modification is cleaved, either by routine manipulation or *in vivo*, yielding the parent compound. Prodrugs include, for example, compounds of this invention wherein hydroxy or amine groups are bonded to any group that, when administered to a patient, cleaves to form the hydroxy or amine groups. Thus, representative examples of prodrugs include (but are not limited to) acetate, formate and benzoate derivatives of alcohol and amine functional groups of the compounds of formula (I). Further, in the case of a carboxylic acid (-COOH), esters may be employed, such as methyl esters, ethyl esters, and the like. Esters may be active in their own right and /or be hydrolysable under *in vivo* conditions in the human body. Suitable pharmaceutically acceptable *in vivo* hydrolysable ester groups include those which break down readily in the human body to leave the parent acid or its salt.

As used herein, the term "alkyl" refers to straight or branched hydrocarbon chains containing the specified number of carbon atoms. For example, C₁₋₆alkyl means a straight or branched alkyl containing at least 1, and at most 6, carbon atoms. Examples of "alkyl" as used herein include, but are not limited to, methyl, ethyl, n-propyl, n-butyl, n-pentyl, isobutyl, isopropyl, t-butyl and hexyl. A C₁₋₄alkyl group is preferred, for example methyl, ethyl, isopropyl or t-butyl. The said alkyl groups may be optionally substituted with one or more fluorine atoms for example, trifluoromethyl.

As used herein, the term "alkoxy" refers to a straight or branched chain alkoxy groups containing the specified number of carbon atoms. For example, C₁₋₆alkoxy means a straight or branched alkoxy containing at least 1, and at most 6, carbon atoms. Examples of "alkoxy" as used herein include, but are not limited to methoxy, ethoxy, propoxy, prop-2-oxy, butoxy, but-2-oxy, 2-methylprop-1-oxy, 2-methylprop-2-oxy, pentoxy, or hexyloxy. A C₁₋₄alkoxy group is preferred, for example methoxy or ethoxy.

As used herein, the term "cycloalkyl" refers to a non-aromatic hydrocarbon ring containing the specified number of carbon atoms which may optionally contain up to one double bond. For example, C₃₋₇cycloalkyl means a non-aromatic ring containing at least three, and at most seven, ring carbon atoms. Examples of "cycloalkyl" as used herein include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. A C₃₋₆cycloalkyl group is preferred, for example, cyclopropyl, cyclopentyl or cyclohexyl.

As used herein, the terms "heteroaryl ring" and "heteroaryl", unless otherwise defined, refer to a monocyclic 5- to 7-membered unsaturated hydrocarbon ring containing at least one heteroatom independently selected from oxygen, nitrogen and sulfur. Preferably, the heteroaryl ring has five or six ring atoms. Examples of heteroaryl rings include, but are not limited to, furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, triazolyl, tetrazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl,

pyrazinyl and triazinyl. The said ring may be optionally substituted by one or more substituents independently selected from C₁₋₆alkyl and oxy.

As used herein, the terms "heterocyclic ring" or "heterocyclyl", unless otherwise defined; refer to a monocyclic 3- to 7-membered saturated hydrocarbon ring containing at least one heteroatom independently selected from oxygen, nitrogen and sulfur. Preferably, the heterocyclyl ring has five or six ring atoms. Examples of heterocyclyl groups include, but are not limited to, aziridinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidyl, piperazinyl, morpholino, tetrahydropyranyl, tetrahydrofuranyl and thiomorpholino. The said ring may be optionally substituted by one or more substituents independently selected from C₁₋₆alkyl and oxy.

As used herein, the terms "halogen" or "halo" refer to the elements fluorine, chlorine, bromine and iodine. Preferred halogens are fluorine, chlorine and bromine. A particularly preferred halogen is fluorine or chlorine.

As used herein, the term "optionally" means that the subsequently described event(s) may or may not occur, and includes both event(s) which occur and events that do not occur.

As used herein, the term "substituted" refers to substitution with the named substituent or substituents, multiple degrees of substitution being allowed unless otherwise stated.


Certain compounds of formula (I) may exist in stereoisomeric forms (e.g. they may contain one or more asymmetric carbon atoms or may exhibit cis-trans isomerism). The individual stereoisomers (enantiomers and diastereomers) and mixtures of these are included within the scope of the present invention. The present invention also covers the individual isomers of the compounds represented by formula (I) as mixtures with isomers thereof in which one or more chiral centres are inverted. Likewise, it is understood that compounds of formula (I) may exist in tautomeric forms other than that shown in the formula and these are also included within the scope of the present invention.

Separation of diastereoisomers or cis and trans isomers may be achieved by conventional techniques, e.g. by fractional crystallisation, chromatography or H.P.L.C. A stereoisomeric mixture of the agent may also be prepared from a corresponding optically pure intermediate or by resolution, such as H.P.L.C. of the corresponding racemate using a suitable chiral support or by fractional crystallisation of the diastereoisomeric salts formed by reaction of the corresponding racemate with a suitable optically active acid or base, as appropriate.

Furthermore, some of the crystalline forms of the compounds of structure (I) may exist as polymorphs, which are included in the present invention.

The compounds of this invention may be made by a variety of methods, including standard chemistry. Any previously defined variable will continue to have the previously defined meaning unless otherwise indicated. Illustrative general synthetic methods are set out below and then specific compounds of the invention are prepared in the working Examples.

A compound of formula (I) may be prepared by reacting a compound of formula (II)



(II)


- 5 in which R¹, R², X and Y are as hereinbefore defined and A¹ is an unsubstituted fused 5-membered heteroaryl ring, with a suitable reagent, for example a halide derivative of formula (III)



(III)


- 10 in which $-(CH_2)_m\text{heterocyclyl}$ is as hereinbefore defined and Z is halogen, in particular chlorine or bromine,
in, for example, the presence of a base such as sodium hydride and a solvent such as DMF.

A compound of formula (I) or a compound of formula (II) may be prepared by reacting a compound of formula (IV)




(IV)

- 15 in which A² is A as hereinbefore defined, in which case the resulting product is a compound of formula (I), A² is A¹ as hereinbefore defined, in which case the resulting product is a compound of formula (II), or A² is a protected form of A or A¹, and Z¹ is halogen, in
20 particular bromine,
with a compound of formula (VA) or (VB)




(VA)



(VB)

in which R^1 , R^2 , X and Y are as hereinbefore defined,
in the presence of a catalyst, for example tetrakis(triphenylphosphine)palladium,
and, if necessary, removing any protecting groups.

A compound of formula (VA) may be prepared by, for example, reacting a compound
of formula (VI)




(VI)

in which R^1 , R^2 , X and Y are as hereinbefore defined and Z^2 is halogen, in particular iodine,
with bis(pinnacolato)diboron, [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium (II)
complex ($PdCl_2(ppdf)$) and potassium acetate in a solvent such as DMF.

A compound of formula (VB) may be prepared by, for example, reacting a compound
of formula (VI) as hereinbefore defined, with n-butyl lithium and triisopropyl borate in a
solvent such as THF.

When R^2 is $-NH-CO-R^5$, a compound of formula (VI) may be prepared by reacting an
amine of formula (VII)



(VII)

in which R^1 , X, Y and Z^2 are as hereinbefore defined,
with an acid compound of formula (VIII)

5



(VIII)


in which R^5 is as hereinbefore defined,
under amide forming conditions.

10

Suitable amide forming conditions are well known in the art and include adding a base such as DIPEA to a mixture of the amine of formula (VII), the acid of formula (VIII), and HATU in a solvent such as DMF.

Alternatively, when R^2 is $-CO-NH-(CH_2)_q-R^6$, a compound of formula (VI) may readily be prepared from a corresponding acid compound of formula (IX)


15



(IX)

in which R^1 , X, Y and Z^2 are as hereinbefore defined,
by converting the acid to an activated form of the acid, for example the acid chloride, by treatment with, for example, thionyl chloride, and then reacting the activated acid thus formed with an amine compound of formula (X)

20



(X)


in which R^6 is as hereinbefore defined,
under amide forming conditions.

25

Suitable amide forming conditions are well known in the art and include treating a solution of the acid of formula (IX), or the activated form thereof, in for example DMF, with an amine of formula (X) in the presence of a base such as triethylamine.

30

A compound of formula (I) may also be prepared by reacting a compound of formula (XI)




(XI)

in which R^1 , R^2 , X and Y are as hereinbefore defined and A^3 is a fused 5-membered heteroaryl ring substituted by $-(CH_2)_m$ heterocyclyl wherein the heterocyclyl is unsubstituted, with a suitable reagent. For example, when $-(CH_2)_m$ heterocyclyl is piperidinyl, the nitrogen atom may be reacted with ethyl isocyanate to form a compound of formula (I).


Alternatively, a further general method comprises final stage modification of one compound of formula (I) into another compound of formula (I). Suitable functional group transformations for converting one compound of formula (I) into another compound of formula (I) are well known in the art and are described in, for instance, *Comprehensive Heterocyclic Chemistry II*, eds. A. R. Katritzky, C. W. Rees and E. F. V. Scriven (Pergamon Press, 1996), *Comprehensive Organic Functional Group Transformations*, eds. A.R. Katritzky, O. Meth-Cohn and C.W. Rees (Elsevier Science Ltd., Oxford, 1995), *Comprehensive Organic Chemistry*, eds. D. Barton and W.D. Ollis (Pergamon Press, Oxford, 1979), and *Comprehensive Organic Transformations*, R.C. Larock (VCH Publishers Inc., New York, 1989).

For example, one general method for preparing the compounds of formula (I) comprises the reaction set out in Scheme 1 below.




Scheme 1

For example, another method for preparing the compounds of formula (I) comprises the reactions set out in Scheme 2 below.




Scheme 2

For example, another method for preparing the compounds of formula (I) comprises the reactions set out in Scheme 3 below.




Scheme 3

For example, another method for preparing the compounds of formula (I) comprises the reactions set out in Scheme 4 below.




Scheme 4

For example, another method for preparing the compounds of formula (I) comprises
5 the reactions set out in Scheme 5 below.



Scheme 5

For example, a further method for preparing the compounds of formula (I) comprises
5 the reactions set out in Scheme 6 below.



Scheme 6

Those skilled in the art will appreciate that in the preparation of the compounds of the invention it may be necessary and/or desirable to protect one or more sensitive groups in the

molecule to prevent undesirable side reactions. Suitable protecting groups for use according to the present invention are well known to those skilled in the art and may be used in a conventional manner. See, for example, "Protective groups in organic synthesis" by T.W. Greene and P.G.M. Wuts (John Wiley & sons 1991) or "Protecting Groups" by P.J. Kocienski (Georg Thieme Verlag 1994). Examples of suitable amino protecting groups include acyl type protecting groups (e.g. formyl, trifluoroacetyl, acetyl), aromatic urethane type protecting groups (e.g. benzyloxycarbonyl (Cbz) and substituted Cbz), aliphatic urethane protecting groups (e.g. 9-fluorenylmethoxycarbonyl (Fmoc), t-butyloxycarbonyl (Boc), isopropyloxycarbonyl, cyclohexyloxycarbonyl) and alkyl type protecting groups (e.g. benzyl, trityl, chlorotriyl). Examples of suitable oxygen protecting groups may include for example alky silyl groups, such as trimethylsilyl or tert-butyldimethylsilyl; alkyl ethers such as tetrahydropyranyl or tert-butyl; or esters such as acetate.

Whilst it is possible for the compounds of the present invention to be administered as the raw chemical, the compounds of formula (I) and their pharmaceutically acceptable derivatives are conveniently administered in the form of pharmaceutical compositions eg when the agent is in admixture with a suitable pharmaceutical excipient, diluent and/or carrier selected with regard to the intended route of administration and standard pharmaceutical practice.

Thus, in another aspect of the invention, we provide a pharmaceutical composition comprising at least one compound of formula (I) or a pharmaceutically acceptable derivative thereof, in association with one or more pharmaceutically acceptable excipients, diluents and/or carriers. The excipient, diluent or carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

According to a further aspect, the invention provides a pharmaceutical composition comprising, as active ingredient, at least one compound of the invention or a pharmaceutically acceptable derivative thereof, in association one or more pharmaceutically acceptable excipients, diluents and/or carriers for use in therapy, and in particular in the treatment of human or animal subjects suffering from a condition susceptible to amelioration by an inhibitor of p38 kinase.

The present invention also provides a pharmaceutical composition comprising a therapeutically effective amount of the compounds of the present invention and a pharmaceutically acceptable excipient, diluent and/or carrier (including combinations thereof).

There is further provided by the present invention a process of preparing a pharmaceutical composition, which process comprises mixing at least one compound of the invention or a pharmaceutically acceptable derivative thereof, together with a pharmaceutically acceptable excipient, diluent and/or carrier.

The pharmaceutical compositions may be for human or animal usage in human and veterinary medicine and will typically comprise any one or more of a pharmaceutically acceptable excipient, diluent or carrier. Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical art, and are described, for example, in Remington's

Pharmaceutical Sciences, Mack Publishing Co. (A. R. Gennaro edit. 1985). The choice of pharmaceutical excipient, diluent or carrier can be selected with regard to the intended route of administration and standard pharmaceutical practice. The pharmaceutical compositions may comprise as – or in addition to – the excipient, diluent or carrier any
5 suitable binder(s), lubricant(s), suspending agent(s), coating agent(s) and solubilising agent(s).

Preservatives, stabilisers, dyes and even flavouring agents may be provided in the pharmaceutical composition. Examples of preservatives include sodium benzoate, sorbic acid and esters of p-hydroxybenzoic acid. Antioxidants and suspending agents may be also
10 used.

For some embodiments, the agents of the present invention may also be used in combination with a cyclodextrin. Cyclodextrins are known to form inclusion and non-inclusion complexes with drug molecules. Formation of a drug-cyclodextrin complex may modify the solubility, dissolution rate, bioavailability and/or stability property of a drug molecule. Drug-
15 cyclodextrin complexes are generally useful for most dosage forms and administration routes. As an alternative to direct complexation with the drug the cyclodextrin may be used as an auxiliary additive, e. g. as a carrier, diluent or solubiliser. Alpha-, beta- and gamma-cyclodextrins are most commonly used and suitable examples are described in WO 91/11172, WO 94/02518 and WO 98/55148.

The compounds of the invention may be milled using known milling procedures such as wet milling to obtain a particle size appropriate for tablet formation and for other formulation types. Finely divided (nanoparticulate) preparations of the compounds of the invention may be prepared by processes known in the art, for example see WO 02/00196 (SmithKline Beecham).
20

There may be different composition/formulation requirements dependent on the different delivery systems. By way of example, the pharmaceutical composition of the present invention may be formulated to be delivered using a mini-pump or by a mucosal route, for example, as a nasal spray or aerosol for inhalation or ingestible solution, or parenterally in which the composition is formulated by an injectable form, for delivery, by, for
25 30 example, an intravenous, intramuscular or subcutaneous route. Alternatively, the formulation may be designed to be delivered by both routes.

Where the agent is to be delivered mucosally through the gastrointestinal mucosa, it should be able to remain stable during transit through the gastrointestinal tract; for example, it should be resistant to proteolytic degradation, stable at acid pH and resistant to the detergent effects of bile.
35

Where appropriate, the pharmaceutical compositions can be administered by inhalation, in the form of a suppository or pessary, topically in the form of a lotion, solution, cream, ointment or dusting powder, by use of a skin patch, orally in the form of tablets containing excipients such as starch or lactose, or in capsules or ovules either alone or in
40 admixture with excipients, or in the form of elixirs, solutions or suspensions containing flavouring or colouring agents, or they can be injected parenterally, for example intravenously, intramuscularly or subcutaneously. For parenteral administration, the

compositions may be best used in the form of a sterile aqueous solution which may contain other substances, for example enough salts or monosaccharides to make the solution isotonic with blood. For buccal or sublingual administration the compositions may be administered in the form of tablets or lozenges which can be formulated in a conventional manner.

The routes for administration (delivery) include, but are not limited to, one or more of: oral (e. g. as a tablet, capsule, or as an ingestible solution), topical, mucosal (e. g. as a nasal spray or aerosol for inhalation), nasal, parenteral (e. g. by an injectable form), gastrointestinal, intraspinal, intraperitoneal, intramuscular, intravenous, intrauterine, intraocular, intradermal, intracranial, intratracheal, intravaginal, intracerebroventricular, intracerebral, subcutaneous, ophthalmic (including intravitreal or intracameral), transdermal, rectal, buccal, epidural and sublingual. It is to be understood that not all of the compounds need be administered by the same route. Likewise, if the composition comprises more than one active component, then those components may be administered by different routes.

The compounds of formula (I) and their pharmaceutically acceptable salts and solvates may be formulated for administration in any suitable manner. They may, for example, be formulated for topical administration or administration by inhalation or, more preferably, for oral, transdermal or parenteral administration. The pharmaceutical composition may be in a form such that it can effect controlled release of the compounds of formula (I) and their pharmaceutically acceptable derivatives. In a preferred embodiment, the agents of the present invention are delivered systemically such as orally, buccally or sublingually. A particularly preferred method of administration, and corresponding formulation, is oral administration.

For oral administration, the pharmaceutical composition may take the form of, and be administered as, for example, tablets (including sub-lingual tablets) and capsules (each including timed release and sustained release formulations), ovules, pills, powders, granules, elixirs, tinctures, emulsions, solutions, syrups or suspensions prepared by conventional means with acceptable excipients for immediate-, delayed-, modified-, sustained-, pulsed- or controlled-release applications.

For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. The tablets may also contain excipients such as microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate and glycine, disintegrants such as starch (preferably corn, potato or tapioca starch), sodium starch glycollate, croscarmellose sodium and certain complex silicates, and granulation binders such as polyvinylpyrrolidone, hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, stearic acid, glyceryl behenate and talc may be included.

Solid compositions of a similar type may also be employed as fillers in gelatin capsules. Preferred excipients in this regard include lactose, starch, a cellulose, milk sugar or high molecular weight polyethylene glycols. For aqueous suspensions and/or elixirs, the

agent may be combined with various sweetening or flavouring agents, colouring matter or dyes, with emulsifying and/or suspending agents and with diluents such as water, ethanol, propylene glycol and glycerin, and combinations thereof.

5 Powders are prepared by comminuting the compound to a suitable fine size and mixing with a similarly comminuted pharmaceutical carrier such as an edible carbohydrate, as, for example, starch or mannitol. Flavoring, preservative, dispersing and coloring agent can also be present.

10 Capsules can be made by preparing a powder mixture as described above, and filling formed gelatin sheaths. Glidants and lubricants such as colloidal silica, talc, magnesium stearate, calcium stearate or solid polyethylene glycol can be added to the powder mixture before the filling operation. A disintegrating or solubilizing agent such as agar-agar, calcium carbonate or sodium carbonate can also be added to improve the availability of the medicament when the capsule is ingested.

15 Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium 20 benzoate, sodium acetate, sodium chloride and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and the like.

Tablets are formulated, for example, by preparing a powder mixture, granulating or slugging, adding a lubricant and disintegrant and pressing into tablets. A powder mixture is prepared by mixing the compound, suitably comminuted, with a diluent or base as described 25 above, and optionally, with a binder such as carboxymethylcellulose, an aliginate, gelatin, or polyvinyl pyrrolidone, a solution retardant such as paraffin, a resorption accelerator such as a quaternary salt and/or an absorption agent such as bentonite, kaolin or dicalcium phosphate. The powder mixture can be granulated by wetting with a binder such as syrup, starch paste, acadia mucilage or solutions of cellulosic or polymeric materials and forcing through a 30 screen. As an alternative to granulating, the powder mixture can be run through the tablet machine and the result is imperfectly formed slugs broken into granules. The granules can be lubricated to prevent sticking to the tablet forming dies by means of the addition of stearic acid, a stearate salt, talc or mineral oil. The lubricated mixture is then compressed into tablets. The compounds of the present invention can also be combined with free flowing 35 inert carrier and compressed into tablets directly without going through the granulating or slugging steps. A clear or opaque protective coating consisting of a sealing coat of shellac, a coating of sugar or polymeric material and a polish coating of wax can be provided. Dyestuffs can be added to these coatings to distinguish different unit dosages.

40 Oral fluids such as solution, syrups and elixirs can be prepared in dosage unit form so that a given quantity contains a predetermined amount of the compound. Syrups can be prepared by dissolving the compound in a suitably flavored aqueous solution, while elixirs are prepared through the use of a non-toxic alcoholic vehicle. Suspensions can be

formulated by dispersing the compound in a non-toxic vehicle. Solubilizers and emulsifiers such as ethoxylated isostearyl alcohols and polyoxy ethylene sorbitol ethers, preservatives, flavor additives such as peppermint oil or saccharin, and the like can also be added.

5 Where appropriate, dosage unit formulations for oral administration can be microencapsulated. The formulation can also be prepared to prolong or sustain the release as for example by coating or embedding particulate material in polymers, wax or the like.

10 The compounds of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.

The compounds of the present invention can also be administered in the form of liposome emulsion delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.

15 Compounds of the present invention may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled. The compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide-phenol, polyhydroxyethylaspartamidephenol, or
20 polyethyleneoxidepolylysine substituted with palmitoyl residues. Furthermore, the compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.

25 The present invention includes pharmaceutical compositions containing 0.1 to 99.5%, more particularly, 0.5 to 90% of a compound of the formula (I) in combination with a pharmaceutically acceptable carrier.

30 Likewise, the composition may also be administered in nasal, ophthalmic, otic, rectal, topical, intravenous (both bolus and infusion), intraperitoneal, intraarticular, subcutaneous or intramuscular, inhalation or insufflation form, all using forms well known to those of ordinary skill in the pharmaceutical arts.

For transdermal administration, the pharmaceutical composition may be given in the form of a transdermal patch, such as a transdermal iontophoretic patch.

35 If the compound of the present invention is administered parenterally, then examples of such administration include one or more of: intravenously, intraarterially, intraperitoneally, intrathecally, intraventricularly, intraurethrally, intrasternally, intracranially, intramuscularly or subcutaneously administering the agent; and/or by using infusion techniques. For parenteral administration, the pharmaceutical composition may be given as an injection or a continuous infusion (e.g. intravenously, intravascularly or subcutaneously). The compositions may take
40 such forms as suspensions, solutions or emulsions in oily or aqueous vehicles and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. For administration by injection these may take the form of a unit dose presentation or as a

multidose presentation preferably with an added preservative. Alternatively for parenteral administration the active ingredient may be in powder form for reconstitution with a suitable vehicle. For parenteral administration, the compound is best used in the form of a sterile aqueous solution which may contain other substances, for example, enough salts or glucose to make the solution isotonic with blood. The aqueous solutions should be suitably buffered (preferably to a pH of from 3 to 9), if necessary. The preparation of suitable parenteral formulations under sterile conditions is readily accomplished by standard pharmaceutical techniques well-known to those skilled in the art.

The compositions of the present invention may be administered by direct injection.

The compounds of the invention may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds of the invention may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

Alternatively the composition may be formulated for topical application, for example in the form of ointments, creams, lotions, eye ointments, eye drops, ear drops, mouthwash, impregnated dressings and sutures and aerosols, and may contain appropriate conventional additives, including, for example, preservatives, solvents to assist drug penetration, and emollients in ointments and creams. Such topical formulations may also contain compatible conventional carriers, for example cream or ointment bases, and ethanol or oleyl alcohol for lotions. Such carriers may constitute from about 1% to about 98% by weight of the formulation; more usually they will constitute up to about 80% by weight of the formulation.

For application topically to the skin, the agent of the present invention can be formulated as a suitable ointment containing the active compound suspended or dissolved in, for example, a mixture with one or more of the following: mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water.

Alternatively, it can be formulated as a suitable lotion or cream, suspended or dissolved in, for example, a mixture of one or more of the following: mineral oil, sorbitan monostearate, a polyethylene glycol, liquid paraffin, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.

For administration by inhalation the compounds according to the invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, a hydrofluoroalkane such as tetrafluoroethane or heptafluoropropane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of e.g. gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.

Alternatively, the compound of the present invention can be administered in the form of a suppository or pessary, or it may be applied topically in the form of a gel, hydrogel, lotion, solution, cream, ointment or dusting powder.

The compounds of the present invention may also be administered by the pulmonary or rectal routes. They may also be administered by the ocular route. For ophthalmic use, the compounds can be formulated as micronised suspensions in isotonic, pH adjusted, sterile saline, or, preferably, as solutions in isotonic, pH adjusted, sterile saline, optionally in combination with a preservative such as a benzylalkonium chloride. Alternatively, they may be formulated in an ointment such as petrolatum.

The pharmaceutical compositions generally are administered in an amount effective for treatment or prophylaxis of a specific condition or conditions. Initial dosing in humans is accompanied by clinical monitoring of symptoms, such symptoms for the selected condition. In general, the compositions are administered in an amount of active agent of at least about 100 µg/kg body weight. In most cases they will be administered in one or more doses in an amount not in excess of about 20 mg/kg body weight per day. Preferably, in most cases, dose is from about 100 µg/kg to about 5 mg/kg body weight, daily. For administration particularly to mammals, and particularly humans, it is expected that the daily dosage level of the active agent will be from 0.1 mg/kg to 10 mg/kg and typically around 1 mg/kg. It will be appreciated that optimum dosage will be determined by standard methods for each treatment modality and indication, taking into account the indication, its severity, route of administration, complicating conditions and the like. The physician in any event will determine the actual dosage which will be most suitable for an individual and will vary with the activity of the specific compound to be employed, the metabolic stability and length of action of that compound, age, weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, severity of the particular condition and response of the particular individual. The effectiveness of a selected actual dose can readily be determined, for example, by measuring clinical symptoms or standard anti-inflammatory indicia after administration of the selected dose. The above dosages are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention. For conditions or disease states as are treated by the present invention, maintaining consistent daily levels in a subject over an extended period of time, e.g., in a maintenance regime, can be particularly beneficial. For oral and parenteral administration to humans, the daily dosage level of the agent may be in single or divided doses.

In another aspect, the present invention provides a compound of formula (I) or a pharmaceutically acceptable derivative thereof, for use in therapy.

The compounds of the present invention are generally inhibitors of the serine/threonine kinase p38 and are therefore also inhibitors of cytokine production which is mediated by p38 kinase. Within the meaning of the term "inhibitors of the serine/threonine kinase p38" are included those compounds that interfere with the ability of p38 to transfer a phosphate group from ATP to a protein substrate according to the assay described below.

It will be appreciated that the compounds of the invention may be selective for one or more of the isoforms of p38, for example p38α, p38β, p38γ and/or p38δ. In one

embodiment, the compounds of the invention selectively inhibit the p38 α isoform. In another embodiment, the compounds of the invention selectively inhibit the p38 β isoform. In a further embodiment, the compounds of the invention selectively inhibit the p38 α and p38 β isoforms. Assays for determining the selectivity of compounds for the p38 isoforms are described in, for example, WO 99/61426, WO 00/71535 and WO 02/46158.

It is known that p38 kinase activity can be elevated (locally or throughout the body), p38 kinase can be incorrectly temporally active or expressed, p38 kinase can be expressed or active in an inappropriate location, p38 kinase can be constitutively expressed, or p38 kinase expression can be erratic; similarly, cytokine production mediated by p38 kinase activity can be occurring at inappropriate times, inappropriate locations, or it can occur at detrimentally high levels.

Accordingly, the present invention provides a compound of formula (I) or a pharmaceutically acceptable derivative thereof for use in the treatment or prophylaxis of a condition or disease state mediated by p38 kinase activity or mediated by cytokines produced by the activity of p38 kinase.

The present invention also provides a method for the treatment of a condition or disease state mediated by p38 kinase activity, or mediated by cytokines produced by the activity of p38 kinase, in a subject which comprises administering to said subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof. The compound may be administered as a single or polymorphic crystalline form or forms, an amorphous form, a single enantiomer, a racemic mixture, a single stereoisomer, a mixture of stereoisomers, a single diastereoisomer or a mixture of diastereoisomers.

The present invention also provides a method of inhibiting cytokine production which is mediated by p38 kinase activity in a subject, e.g. a human, which comprises administering to said subject in need of cytokine production inhibition a therapeutic, or cytokine-inhibiting, amount of a compound of the present invention. The compound may be administered as a single or polymorphic crystalline form or forms, an amorphous form, a single enantiomer, a racemic mixture, a single stereoisomer, a mixture of stereoisomers, a single diastereoisomer or a mixture of diastereoisomers.

The present invention treats these conditions by providing a therapeutically effective amount of a compound of this invention. By "therapeutically effective amount" is meant a symptom-alleviating or symptom-reducing amount, a cytokine-reducing amount, a cytokine-inhibiting amount, a kinase-regulating amount and/or a kinase-inhibiting amount of a compound. Such amounts can be readily determined by standard methods, such as by measuring cytokine levels or observing alleviation of clinical symptoms. For example, the clinician can monitor accepted measurement scores for anti-inflammatory treatments. It will be appreciated that reference to treatment includes acute treatment or prophylaxis as well as the alleviation of established symptoms.

The compounds of the present invention can be administered to any subject in need of inhibition or regulation of p38 kinase or in need of inhibition or regulation of p38 mediated cytokine production. In particular, the compounds may be administered to mammals. Such

mammals can include, for example, horses, cows, sheep, pigs, mice, dogs, cats, primates such as chimpanzees, gorillas, rhesus monkeys, and, most preferably, humans.

Thus, the present invention provides methods of treating or reducing symptoms in a human or animal subject suffering from, for example, rheumatoid arthritis, osteoarthritis, asthma, psoriasis, eczema, allergic rhinitis, allergic conjunctivitis, adult respiratory distress syndrome, chronic pulmonary inflammation, chronic obstructive pulmonary disease, chronic heart failure, silicosis, endotoxemia, toxic shock syndrome, inflammatory bowel disease, tuberculosis, atherosclerosis, neurodegenerative disease, Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, epilepsy, multiple sclerosis, aneurism, stroke, irritable bowel syndrome, muscle degeneration, bone resorption diseases, osteoporosis, diabetes, reperfusion injury, graft vs. host reaction, allograft rejections, sepsis, systemic cachexia, cachexia secondary to infection or malignancy, cachexia secondary to acquired immune deficiency syndrome (AIDS), malaria, leprosy, infectious arthritis, leishmaniasis, Lyme disease, glomerulonephritis, gout, psoriatic arthritis, Reiter's syndrome, traumatic arthritis, rubella arthritis, Crohn's disease, ulcerative colitis, acute synovitis, gouty arthritis, spondylitis, and non articular inflammatory conditions, for example, herniated/ruptured/prolapsed intervertebral disk syndrome, bursitis, tendonitis, tenosynovitis, fibromyalgic syndrome and other inflammatory conditions associated with ligamentous sprain and regional musculoskeletal strain, pain, for example that associated with inflammation and/or trauma, osteopetrosis, restenosis, thrombosis, angiogenesis, cancer including breast cancer, colon cancer, lung cancer or prostatic cancer, which comprises administering to said subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof.

A further aspect of the invention provides a method of treatment of a human or animal subject suffering from rheumatoid arthritis, asthma, psoriasis, chronic pulmonary inflammation, chronic obstructive pulmonary disease, chronic heart failure, systemic cachexia, glomerulonephritis, Crohn's disease, neurodegenerative disease, Alzheimer's disease, Parkinson's disease, epilepsy and cancer including breast cancer, colon cancer, lung cancer and prostatic cancer, which comprises administering to said subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof.

A further aspect of the invention provides a method of treatment of a human or animal subject suffering from rheumatoid arthritis, asthma, psoriasis, chronic pulmonary inflammation, chronic obstructive pulmonary disease, chronic heart failure, systemic cachexia, glomerulonephritis, Crohn's disease and cancer including breast cancer, colon cancer, lung cancer and prostatic cancer, which comprises administering to said subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof.

A further aspect of the invention provides a method of treatment of a human or animal subject suffering from rheumatoid arthritis, asthma, chronic pulmonary inflammation, chronic obstructive pulmonary disease, neurodegenerative disease, Alzheimer's disease, Parkinson's disease and epilepsy which comprises administering to said subject a

therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof.

A further aspect of the invention provides a method of treatment of a human or animal subject suffering from any type of pain including chronic pain, rapid onset of analgesis, neuromuscular pain, headache, cancer pain, acute and chronic inflammatory pain associated with osteoarthritis and rheumatoid arthritis, post operative inflammatory pain, neuropathic pain, diabetic neuropathy, trigeminal neuralgia, post-hepatic neuralgia, inflammatory neuropathies and migraine pain which comprises administering to said subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof.

A further aspect of the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable derivative thereof, in the manufacture of a medicament for use in the treatment of a condition or disease state mediated by p38 kinase activity or mediated by cytokines produced by p38 kinase activity.

The compounds of formula (I) and their derivatives may be employed alone or in combination with other therapeutic agents for the treatment of the above-mentioned conditions. The invention thus provides, in a further aspect, a combination comprising a compound of the invention or a pharmaceutically acceptable derivative thereof together with a further therapeutic agent.

In particular, in rheumatoid arthritis therapy, combination with other chemotherapeutic or antibody agents is envisaged. Combination therapies according to the present invention thus comprise the administration of at least one compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof and at least one other pharmaceutically active agent. The compound(s) of formula (I) or pharmaceutically acceptable salt(s) or solvate(s) thereof and the other pharmaceutically active agent(s) may be administered together or separately and, when administered separately, this may occur separately or sequentially in any order. The amounts of the compound(s) of formula (I) or pharmaceutically acceptable salt(s) or solvate(s) thereof and the other pharmaceutically active agent(s) and the relative timings of administration will be selected in order to achieve the desired combined therapeutic effect. Appropriate doses will be readily appreciated by those skilled in the art. It will be appreciated that the amount of a compound of the invention required for treatment will vary with the nature of the condition being treated and the age and condition of the patient and will ultimately be at the discretion of the attendant physician or veterinarian. Examples of other pharmaceutically active agents which may be employed in combination with compounds of formula (I) and their salts and solvates for rheumatoid arthritis therapy include: immunosuppressants such as amtolmetin guacil, mizoribine and rimexolone; anti-TNF α agents such as etanercept, infliximab, diacerein; tyrosine kinase inhibitors such as leflunomide; kallikrein antagonists such as subreum; interleukin 11 agonists such as oprelvekin; interferon beta 1 agonists; hyaluronic acid agonists such as NRD-101 (Aventis); interleukin 1 receptor antagonists such as anakinra; CD8 antagonists such as amiprilose hydrochloride; beta amyloid precursor protein antagonists such as reumacon; matrix metalloprotease inhibitors such as cipemastat and other disease modifying anti-rheumatic

drugs (DMARDs) such as methotrexate, sulphasalazine, cyclosporin A, hydroxychloroquine, auranofin, aurothioglucose, gold sodium thiomalate and penicillamine.

5 The combinations referred to above may conveniently be presented for use in the form of a pharmaceutical formulation and thus pharmaceutical formulations comprising a combination as defined above together with a pharmaceutically acceptable carrier or excipient comprise a further aspect of the invention.

The individual components of such combinations may be administered either sequentially or simultaneously in separate or combined pharmaceutical formulations by any convenient route.

10 When administration is sequential, either the compound of the invention or the second therapeutic agent may be administered first. When administration is simultaneous, the combination may be administered either in the same or different pharmaceutical composition.

15 When combined in the same formulation it will be appreciated that the two compounds must be stable and compatible with each other and the other components of the formulation. When formulated separately they may be provided in any convenient formulation, conveniently in such manner as are known for such compounds in the art.

EXAMPLES

The following Examples are illustrative embodiments of the invention, not limiting the scope of the invention in any way. Reagents are commercially available or are prepared according to procedures in the literature.

5-Bromoindazole may be prepared by the procedure described by A. Arnautu *et al.* in Tetrahedron Letters, 2002, 43, 2695.


{5-[(Cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}boronic acid may be prepared by the procedure described in WO 03/068747.

2-(Bromomethyl)tetrahydro-2H-pyran may be purchased from Aldrich.

2-(Bromomethyl)tetrahydrofuran may be purchased from Lancaster.

4-Benzyl-2-(chloromethyl)morpholine may be purchased from Maybridge International.


LCMS was conducted on a column (3.3cm x 4.6mm ID, 3µm ABZ+PLUS), at a Flow Rate of 3ml/min, Injection Volume of 5µl, at room temperature and UV Detection Range at 215 to 330nm. Solvent A: 10mM Aqueous ammonium acetate + 0.1% formic acid. Solvent B: 95% Acetonitrile + 0.05% formic acid. Gradient : 0% A/0.7min, 0-100% A/3.5min, 100% A/1.1min, 100-0% A/0.2min.

Intermediate 1: tert-Butyl 5-bromo-1H-indazole-1-carboxylate

A stirred ice-cold suspension of 5-bromoindazole (2g), 4-(dimethylamino)pyridine (250mg) and triethylamine (1.55ml) in acetonitrile (50ml) was treated with a solution of di-tert-butyl dicarbonate (2.8ml) in acetonitrile (20ml) over 15min such that the temperature remained under 5°C. The reaction mixture was warmed to room temperature then stirred for 18h. The solvent was evaporated and the residue was purified by column chromatography on silica (100g) eluting with cyclohexane:ethyl acetate (15:1) to give the title compound (2.27g).


LC-MS: Rt 3.55min.

Intermediate 2: 1,1-Dimethylethyl 5-{5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}-1H-indazole-1-carboxylate




A mixture of tert-butyl 5-bromo-1H-indazole-1-carboxylate (Intermediate 1, 1.07g), {5-
 5 [(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}boronic acid (0.85g), sodium
 carbonate (1.9g) and tetrakis(triphenylphosphine)palladium(0) (0.42g) in 1,2-
 dimethoxyethane (70ml) was stirred at reflux under nitrogen for 20h. The solvent was
 removed and the residue was partitioned between water (50ml) and ethyl acetate (50ml).
 The aqueous layer was re-extracted with ethyl acetate (3x30ml) and the combined organic
 extracts were dried using a hydrophobic filter tube and concentrated under vacuum. The
 residue was purified by column chromatography on silica eluting with cyclohexane:ethyl
 acetate (75:25 to 60:40) to give the title compound (3.1g).
 LC-MS: Rt 3.46min, MH+ 410.

Intermediate 3: *N*-Cyclopropyl-3-fluoro-5-(1H-indazol-5-yl)-4-methylbenzamide




A mixture of 1,1-dimethylethyl 5-{5-[(cyclopropylamino)carbonyl]-3-fluoro-2-
 methylphenyl}-1H-indazole-1-carboxylate (Intermediate 2, 0.46g) in a solution of hydrogen
 chloride in dioxane (4M, 7ml) was stirred at room temperature under nitrogen for 4.5h. The
 solvent was evaporated and the residue was partitioned between dichloromethane (20ml)
 and aqueous sodium hydroxide (2M, 20ml). The organic layer was separated using a
 hydrophobic filter tube, the solvent was evaporated and the residue was purified on a Varian
 Bond-Elut SPE cartridge (silica, 10g) eluting with chloroform:methanol (100:0 to 98:2) to give
 the title compound (0.06g).
 LC-MS: Rt 2.96min, MH+ 310.

Intermediate 4: N-Ethyl-3-fluoro-5-iodo-4-methylbenzamide


- 5 3-Fluoro-5-iodo-4-methylbenzoic acid (Intermediate 11, 20g) in thionyl chloride (20ml) was heated at 110°C for 1h. The excess thionyl chloride was evaporated under vacuum and the residual oil was dissolved in DCM (100ml). Potassium carbonate (21g) was added to the solution followed by the slow addition of ethylamine (2M in THF, 70ml). The reaction was left at room temperature overnight, filtered and the residue was washed with ethyl acetate. The combined filtrate and washings were reduced to dryness under vacuum and the resulting solid was washed with ether/cyclohexane (1:1) to give the title compound as a pale beige solid (18.5g).
 10 NMR: [δ H d_6 -DMSO] 8.58(1H, b), 8.15(1H, s), 7.64(1H, d), 3.26(2H, quin), 2.33(3H, s), 1.11(3H, t).

15

Intermediate 5: N-Ethyl-3-fluoro-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide


- 20 N-Ethyl-3-fluoro-5-iodo-4-methylbenzamide (Intermediate 4, 10.9g), bispinnacolcatodiborane (9.9g), Pd(dppf)Cl₂ (600mg) and potassium acetate (17.3g) were mixed in DMF (210ml). The mixture was degassed and then heated at 85°C under nitrogen for 18h. The cooled reaction was absorbed onto silica and applied to a silica column, eluting with an ethyl acetate/cyclohexane gradient (5-25% ethyl acetate). The resultant product was recrystallised from cyclohexane to give the title compound as a white solid (2.83g).
 25 NMR: [δ H d_6 -DMSO] 8.54(1H, bt), 7.94(1H, s), 7.68(1H, d), 3.27(2H, quin), 2.42(3H, s), 1.32(12H, s), 1.11(3H, t).

Intermediate 6: 1,1-Dimethylethyl 4-(6-bromo-1H-indazol-3-yl)-1-piperazinecarboxylate



A solution of 6-bromo-2-nitro-2*H*-indazole (50mg) and 1,1-dimethylethyl 1-piperazinecarboxylate (107mg) in THF (1ml) was stirred at reflux for 18h. Additional 1,1-dimethylethyl 1-piperazinecarboxylate (107mg) and DMAP (~10mg) were added and heating was continued for 24h. The mixture was diluted with methanol then purified by reverse phase preparative HPLC to give the title compound as a yellow oil (28mg).
LC-MS: Rt 3.5min, MH⁺ 382.


Intermediate 7: (4-Bromo-2-fluorophenyl)(tetrahydro-3-furanyl)methanone



Tetrahydro-3-furoic acid (500mg) in thionyl chloride (3mL) was stirred at 110°C under nitrogen for 1.5h. The solvent was evaporated to give the tetrahydro-3-furancarbonyl chloride as a brown oil (480mg). A solution of 4-bromo-2-fluorophenyl(iodo)zinc in tetrahydrofuran (0.5M, 7.16mL) was added slowly to a stirred mixture of the tetrahydro-3-furancarbonyl chloride (480mg) and tetrakis(triphenylphosphine)palladium(0) (206mg) in tetrahydrofuran (2mL) at room temperature under nitrogen. The mixture was stirred at room temperature under nitrogen for 1h, then aqueous ammonium chloride (1M, 10mL) was added. The mixture was extracted with ethyl acetate (2x10mL), the organic phases was dried using a hydrophobic filter tube and the solvent was removed under vacuum. The residue was purified by chromatography on a silica column, eluting with a cyclohexane:ethyl acetate gradient, to give the title compound as a brown oil (850mg).


LC-MS: Rt 2.92min.

Intermediate 8: 1,1-Dimethylethyl 2-[(4-bromo-2-fluorophenyl)(tetrahydro-3-furanyl)methylidene]hydrazinecarboxylate




A mixture of ((4-bromo-2-fluorophenyl)(tetrahydro-3-furanyl)methanone (Intermediate 7, 850mg) 1,1-dimethylethyl hydrazinecarboxylate (616mg) and acetic acid (1mL) in methanol (5mL) was stirred at reflux under nitrogen for 20h. The solvent was removed under vacuum and the residue was partitioned between ethyl acetate and water. The organic phase was washed with sodium bicarbonate (1M, 10mL), dried using a hydrophobic filter tube and concentrated under vacuum to give the title compound as a brown oil (1.1g).
LC-MS: Rt 3.13min.

Intermediate 9: 6-Bromo-3-(tetrahydro-3-furanyl)-1H-indazole




A mixture of 1,1-dimethylethyl 2-[(4-bromo-2-fluorophenyl)(tetrahydro-3-furanyl)methylidene]hydrazinecarboxylate (Intermediate 8, 1.1g) and 1,8-diazabicyclo[5.4.0]undec-7-ene (424μL) in tetrahydrofuran (12mL) in a sealed vial was heated in a microwave oven at 150°C for 30min. The reaction mixture was partitioned between ethyl acetate (15mL) and water (15mL) and the organic layer was dried using a hydrophobic filter tube and concentrated under vacuum. The residue was purified by chromatography on a silica column, eluting with a cyclohexane:ethyl acetate gradient, to give the title compound as a colourless glass (405mg).
LC-MS: Rt 2.92min.

Intermediate 10: N-Ethyl-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide




4-Methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid (1.3g) 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (1.44g) and 3H-[1,2,3] 1-hydroxy-7-azabenzotriazole (0.077g) was added to a stirred solution of ethylamine in tetrahydrofuran (2M, 5ml) in chloroform (30ml) and the mixture was stirred for 24h. The mixture was poured into water, passed through a hydrophobic filter tube and the organic phase was concentrated under vacuum.. The residual solid was purified on an SCX cartridge eluting with methanol to give the title compound as a pale yellow solid (1.36g) LC-MS: Rt 3.2min.

Intermediate 11: 3-Fluoro-5-iodo-4-methylbenzoic acid



A solution of 3-fluoro-4-methylbenzoic acid (149.7g) in trifluoromethanesulphonic acid (1050ml) at -22°C under nitrogen was treated portionwise over 1.25h with iodosuccinimide (203.5g). The mixture was stirred at -20°C for and further portions of iodosuccinimide were added after 2.5h (46.5g) and 20.5h (30g). The mixture was stirred at -20°C for a further 24h then added slowly to a mixture of aqueous sodium thiosulphate (10%, 1.5L) and ice (3kg). The resultant precipitate was collected by filtration and stirred with ethyl acetate (5L) and aqueous sodium thiosulphate (10%, 1.5L). The organic phase was dried (MgSO₄) and concentrated to ~1.5L then left overnight. The precipitate was collected by filtration and further material was obtained through concentration of the filtrate to give the title compound as a white solid (133.9g). LC-MS: Rt 3.60, MH⁺ 281.

Intermediate 12: N-Ethyl-3-(1H-indazol-6-yl)-4-methylbenzamide




A stirred mixture of 6-iodo-1H-indazole (0.45g), N-ethyl-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (Intermediate 10, 0.54g) tetrakis(triphenylphosphine)palladium(0) (0.05g) and aqueous sodium hydrogen carbonate (1M, 1ml) in isopropanol (10ml) was heated at 150°C for 30min in a microwave oven. The

reaction mixture was poured into water (50ml) and extracted with ethyl acetate (3x25ml). The extracts were washed with water (25ml) dried (Na_2SO_4) and concentrated under vacuum. The residual oil was purified by column chromatography on silica (50g) eluting with ether/ethyl acetate (7:3) to give the title compound as a pale yellow foam (0.25g).

5 LC-MS: Rt 2.7min.


Intermediate 13: N-Ethyl-3-(3-iodo-1H-indazol-6-yl)-4-methylbenzamide



Iodine (1.35g) was added to a stirred solution of N-ethyl-3-(1H-indazol-6-yl)-4-methylbenzamide (Intermediate 12, 1.1g) in 1,4-dioxan (20ml) and aqueous sodium hydroxide (2M, 20ml) then stirred at room temperature for 10min. The reaction mixture was treated with aqueous sodium bisulphite (10%, 25ml) and aqueous citric acid (10%, 25ml). The mixture was extracted with ethyl acetate (3x25ml) and the organic extracts were washed with water (30ml) dried (Na_2SO_4) and concentrated under vacuum to give the title compound (1.54g).

15 LC-MS: Rt 3.29min, MH^+ 406.

Intermediate 14: 1,1-Dimethylethyl 4-(6-{5-[(ethylamino)carbonyl]-2-methylphenyl}-1H-indazol-3-yl)-3,6-dihydro-1(2H)-pyridinecarboxylate




A mixture of N-ethyl-3-(3-iodo-1H-indazol-6-yl)-4-methylbenzamide (Intermediate 13, 1.1g), 1,1-dimethylethyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-1(2H)-pyridinecarboxylate (Intermediate 10, 0.84g), aqueous sodium hydrogen carbonate (1M, 5.4mL) and tetrakis(triphenylphosphine)palladium(0) (63mg) in isopropanol (15ml) in a sealed vial was stirred at 150°C for 30 min in a microwave oven. The solvent was removed

under vacuum and the residue was partitioned between ethyl acetate/chloroform (1:1) and water. The organic layer was separated using a hydrophobic filter tube, the solvent was evaporated and the residual solid was purified by column chromatography on silica eluting with an ethyl acetate:cyclohexane gradient to give the title compound as a yellow solid (0.86g).

LC-MS: Rt 3.79min MH+ 461.


Intermediate 15: *N*-Ethyl-4-methyl-3-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1*H*-indazol-6-yl]benzamide



A solution of 1,1-dimethylethyl 4-(6-{5-[(ethylamino)carbonyl]-2-methylphenyl}-1*H*-indazol-3-yl)-3,6-dihydro-1(2*H*)-pyridinecarboxylate (Intermediate 14, 550mg) in dichloromethane (10ml) under nitrogen was treated dropwise with trifluoroacetic acid (0.89ml) then stirred at room temperature for 2h. More trifluoroacetic acid (0.89ml) was added and stirring was continued for a further 1h. The solvent was evaporated and the residue was dissolved in methanol and applied to an SCX ion exchange cartridge. Elution with a solution of aqueous ammonia (0.88) in methanol (10%) gave the title compound as a white solid (432mg).

LC-MS: Rt 2.23min, MH+ 361.

Intermediate 16: *N*-Ethyl-4-methyl-3-[3-(4-piperidiny)-1*H*-indazol-6-yl]benzamide




A solution of *N*-ethyl-4-methyl-3-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1*H*-indazol-6-yl]benzamide (Intermediate 15, 360mg) in ethanol (10ml) and DMF (3ml) was stirred with 10% palladium on carbon (50mg) under an atmosphere of hydrogen for 24h. The catalyst

was removed by filtration, the solvent was evaporated and the residue was dissolved in methanol and applied to an SCX ion exchange cartridge. The cartridge was eluted with a solution of aqueous ammonia (0.88) in methanol (10%) and the resultant product was further purified on a column of silica, eluting with a dichloromethane/methanol gradient, to give the title compound (210mg).

LC-MS: Rt 2.31min, MH⁺ 363.


Intermediate 17: {5-[(Ethylamino)carbonyl]-3-fluoro-2-methylphenyl}boronic acid



Sodium hydride (60% in mineral oil, 1.23g) was added in portions to a solution of N-ethyl-3-fluoro-5-iodo-4-methylbenzamide (Intermediate 4, 4.81g) in anhydrous THF (75ml). The resulting mixture was cooled to -75°C and n-butyllithium (1.6M in hexanes, 20ml) was added dropwise over 20min. Triisopropylborate (8ml) was added over 5min and the reaction mixture was stirred at -75°C for 6h. Water (20 ml) was added and the mixture was warmed to 15°C overnight and the mixture was partitioned between saturated aqueous ammonium chloride and ethyl acetate. The organic phase was washed with aqueous ammonium chloride and brine, dried (MgSO₄) and concentrated under vacuum. The residue was dissolved in dichloromethane and applied to a silica column (10g) eluting with an ethyl acetate/dichloromethane gradient (0-100% ethyl acetate) followed by methanol. The methanol fractions were concentrated under vacuum to give the title compound as an off-white foam (550mg).

NMR: [δH d₄-MeOH] 7.55(1H, s), 7.48(1H, d), 3.38(2H, q), 3.30(2H, b), 2.28(3H, s), 1.20(3H, t).


Intermediate 18: N-Ethyl-3-fluoro-5-(1H-indazol-6-yl)-4-methylbenzamide



A stirred mixture of 6-iodo-1H-indazole (0.5g, {5-[(ethylamino)carbonyl]-3-fluoro-2-methylphenyl}boronic acid (Intermediate 17, 0.56g), tetrakis(triphenylphosphine)palladium(0)

(0.05g) and aqueous sodium hydrogen carbonate (1M, 1ml) in isopropanol (10ml) was heated at 150°C for 30min in a microwave oven. The reaction mixture was poured into water (30ml) and extracted with ethyl acetate (3x20ml). The extracts were dried (Na₂SO₄) and concentrated under vacuum. The residual oil was purified by column chromatography on silica (50g) eluting with ether/ethyl acetate (4:1). The resultant product was triturated with a small quantity of dichloromethane to give the title compound as a pale yellow solid (0.15g).
LC-MS: Rt 2.96min, MH⁺ 298.

Intermediate 19: N-Ethyl-3-fluoro-5-(3-iodo-1H-indazol-6-yl)-4-methylbenzamide




10

Iodine (0.153g) was added to a stirred solution of N-ethyl-3-fluoro-5-(1H-indazol-6-yl)-4-methylbenzamide (Intermediate 18, 0.15g) in 1,4-dioxan (4ml) and aqueous sodium hydroxide (2M, 4ml) then stirred at room temperature for 45min. The reaction mixture was treated aqueous citric acid (20%, 20ml) followed by sodium metabisulphite (2g). The mixture was diluted with water then extracted with ethyl acetate (2x30ml). The organic extracts were washed with water (30ml) dried (Na₂SO₄) and concentrated under vacuum to give the title compound as a pale yellow foam (0.21g).
LC-MS: Rt 3.41min, MH⁺ 424.

20


Intermediate 20: 1,1-Dimethylethyl 4-(6-{5-[(ethylamino)carbonyl]-3-fluoro-2-methylphenyl}-1H-indazol-3-yl)-3,6-dihydro-1(2H)-pyridinecarboxylate



A mixture of *N*-ethyl-3-fluoro-5-(3-iodo-1*H*-indazol-6-yl)-4-methylbenzamide (Intermediate 19, 2.34g), 1,1-dimethylethyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-1(2*H*)-pyridinecarboxylate (1.71g), aqueous sodium hydrogen carbonate (1M, 11.1ml) and tetrakis(triphenylphosphine)palladium(0) (129mg) in isopropanol (10ml) was divided into three portions then stirred in sealed vials at 150°C for 25 min in a microwave oven. The reaction mixtures were combined, the solvent was removed under vacuum and the residue was partitioned between ethyl acetate and water. The organic layer was separated using a hydrophobic filter tube, the solvent was evaporated and the residue was purified by chromatography on a silica column eluting with an ethyl acetate:cyclohexane gradient, to give the title compound as a yellow foam (1.76g).

LC-MS: Rt 3.7min.


Intermediate 21: N-Ethyl-3-fluoro-4-methyl-5-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1*H*-indazol-6-yl]benzamide



Trifluoroacetic acid (2.73ml) was added dropwise to a solution of 1,1-dimethylethyl 4-(6-{5-[(ethylamino)carbonyl]-3-fluoro-2-methylphenyl}-1*H*-indazol-3-yl)-3,6-dihydro-1(2*H*)-pyridinecarboxylate (Intermediate 20, 50mg) in dichloromethane (10ml) at room temperature under nitrogen then stirred at room temperature for 1h. More trifluoroacetic acid (1.73ml) was added and the mixture was stirred at room temperature under nitrogen for a further 1h. The solvent was removed and the residue was dissolved in methanol and applied to an SCX ion exchange cartridge. Elution with a solution of ammonia (0.88) in methanol gave the title compound as a white solid (1.15g).


LC-MS: 2.34min, MH⁺ 379.

Intermediate 22: N-Ethyl-3-fluoro-4-methyl-5-[3-(4-piperidinyl)-1*H*-indazol-6-yl]benzamide




A mixture of N-ethyl-3-fluoro-4-methyl-5-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indazol-6-yl]benzamide (Intermediate 21, 100mg), 10% palladium on carbon (20mg) and ammonium formate (50mg) in ethanol (10mL) was stirred at 90°C for 1h under nitrogen. The catalyst was removed by filtration and the filtrate was concentrated under vacuum. The product was dissolved in methanol and eluted through an SCX ion exchange cartridge. Elution with a solution of ammonia (0.88) in methanol gave the title compound as a white solid (89mg). LC-MS: Rt 2.30min, MH⁺ 381.

Example 1: N-Cyclopropyl-3-fluoro-4-methyl-5-[1-(tetrahydro-2H-pyran-2-ylmethyl)-1H-indazol-5-yl]benzamide




Sodium hydride (60% in mineral oil, 12mg) was added to N-cyclopropyl-3-fluoro-5-(1H-indazol-5-yl)-4-methylbenzamide (Intermediate 3, 45mg) in DMF (5ml) and the mixture was stirred at room temperature for 1 h. 2-(Bromomethyl)tetrahydro-2H-pyran (20.5μl) was added and stirring continued for 18h. The mixture was diluted with chloroform/ethyl acetate (1:1, 5ml) and washed with water (2x5ml). The organic phase was concentrated under vacuum and the residue was purified by preparative HPLC to give the title compound as a colourless glass (23mg). LC-MS: Rt 3.35min, MH⁺ 408.

Example 2: N-Cyclopropyl-3-fluoro-4-methyl-5-[1-(tetrahydro-2-furanylmethyl)-1H-indazol-5-yl]benzamide




The procedure for Example 1 was followed using sodium hydride (60% in mineral oil, 12mg), *N*-cyclopropyl-3-fluoro-5-(1*H*-indazol-5-yl)-4-methylbenzamide (Intermediate 3, 45mg) and 2-(bromomethyl)tetrahydrofuran (26mg) in DMF (5ml) to give the title compound as a colourless glass (17mg).
LC-MS: Rt 3.15min, MH⁺ 394.

Example 3: 3-{1-[(4-Benzylmorpholin-2-yl)methyl]-1*H*-indazol-5-yl}-*N*-cyclopropyl-5-fluoro-4-methylbenzamide



The procedure for Example 1 was followed using sodium hydride (60% in mineral oil, 19.4mg), *N*-cyclopropyl-3-fluoro-5-(1*H*-indazol-5-yl)-4-methylbenzamide (Intermediate 3, 100mg) and 4-benzyl-2-(chloromethyl)morpholine (87.6mg) in DMF (5ml) to give the crude product (70mg). A portion (10mg) was subjected to preparative HPLC to give the title compound as a white solid (7.6mg).
LC-MS: Rt 2.65min, MH⁺ 499.


Example 4: 1,1-Dimethylethyl 4-(6-{5-[(ethylamino)carbonyl]-3-fluoro-2-methylphenyl}-1*H*-indazol-3-yl)-1-piperazinecarboxylate




A mixture of 1,1-dimethylethyl 4-(6-bromo-1H-indazol-3-yl)-1-piperazinecarboxylate (Intermediate 6, 28mg), N-ethyl-3-fluoro-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (Intermediate 5, 27mg), tetrakis(triphenylphosphine)palladium (2mg) and aqueous sodium hydrogen carbonate (0.125ml) in isopropanol (0.5ml) was heated at 150°C in a microwave oven for 15min. Water and DCM were added and the organic phase was separated using a hydrophobic filter tube. The solvent was evaporated and the residue was purified by reverse phase preparative HPLC to give the title compound (16mg).

LC-MS: Rt 3.3min, MH⁺ 482.


Example 5: N-Ethyl-4-methyl-3-[3-(tetrahydro-3-furanyl)-1H-indazol-6-yl]benzamide



A mixture of 6-bromo-3-(tetrahydro-3-furanyl)-1H-indazole (Intermediate 9, 84mg) N-ethyl-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (Intermediate 10, 91mg) aqueous sodium hydrogen carbonate (1M, 630μL) and tetrakis(triphenylphosphine)palladium(0) (7mg) in isopropanol (4ml) in a sealed vial was stirred at 150°C for 15 min in a microwave oven. The solvent was removed under vacuum and the residue was purified by chromatography on a silica column, eluting with a cyclohexane:ethyl acetate gradient, to give the title compound as a white solid (36mg).
LC-MS: Rt 2.84min, MH⁺ 350.

Example 6: N-Ethyl-3-fluoro-4-methyl-5-[3-(tetrahydro-3-furanyl)-1H-indazol-6-yl]benzamide

- 5 A mixture of 6-bromo-3-(tetrahydro-3-furanyl)-1H-indazole (Intermediate 9, 84mg) N-ethyl-3-fluoro-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (Intermediate 5, 97mg) aqueous sodium hydrogen carbonate (1M, 630 μ L) and tetrakis(triphenylphosphine)palladium (7mg) in isopropanol (4ml) in a sealed vial was stirred at 150°C for 15 min in a microwave oven. The solvent was removed under vacuum and the
- 10 residue purified by chromatography on a silica column eluting with cyclohexane:ethyl acetate (50:50 to 0:100) to give the title compound as a white solid (44mg).
LC-MS: Rt 2.95min, MH⁺ 368.


Example 7: 1,1-Dimethylethyl 4-(6-(5-[(ethylamino)carbonyl]-2-methylphenyl)-1H-indazol-3-yl)-1-piperazinecarboxylate

- 20 A mixture of 1,1-dimethylethyl 4-(6-bromo-1H-indazol-3-yl)-1-piperazinecarboxylate (Intermediate 6, 660mg) N-ethyl-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (Intermediate 10, 598mg) tetrakis(triphenylphosphine)palladium (25mg) and aqueous sodium hydrogen carbonate (1M, 1.5ml) in isopropanol (6ml) was stirred at 150°C for 20min in a microwave oven. DCM and water were added and the organic phase was separated using a hydrophobic filter tube and concentrated under vacuum. The residue was

purified by chromatography on a silica column eluting with a cyclohexane/ethyl acetate gradient to give the title compound (660mg).

LC-MS: Rt 3.3min, MH⁺ 464.


5 **Example 8: N-Ethyl-4-(6-{5-[(ethylamino)carbonyl]-2-methylphenyl}-1H-indazol-3-yl)-1-piperidinecarboxamide**



10 Ethyl isocyanate (4μL) was added to N-ethyl-4-methyl-5-[3-(4-piperidinyl)-1H-indazol-6-yl]benzamide (Intermediate 16, 20mg) in DMF (3mL) at room temperature under nitrogen and the reaction mixture was stirred at room temperature for 30min. The product was concentrated under vacuum and the residue was purified by preparative HPLC to give the title compound as a white solid (13mg).

LC-MS: Rt 2.75min, MS⁺ 434.

15 **Example 9: N-Ethyl-4-(6-{5-[(ethylamino)carbonyl]-3-fluoro-2-methylphenyl}-1H-indazol-3-yl)-1-piperidinecarboxamide**



20 A mixture of ethyl isocyanate (6.5μL) and N-ethyl-3-fluoro-4-methyl-5-[3-(4-piperidinyl)-1H-indazol-6-yl]benzamide (Intermediate 22, 30mg) in DMF (3mL) was stirred at room temperature under nitrogen for 30min. The solvent was removed under vacuum and the residue was purified by preparative HPLC to give the title compound as a white solid (18mg).

25 LC-MS: Rt 2.93min, MS⁺ 452.

Abbreviations

	BOC	t-Butoxycarbonyl
5	CDI	Carbonyldiimidazole
	DBU	1,8-Diazabicyclo[5.4.0]undec-7-ene
	DCM	Dichloromethane
	DIPEA	N,N-Diisopropylethylamine
	DMAP	4-Dimethylaminopyridine
10	DMF	Dimethylformamide
	Et	Ethyl
	h	Hours
	Hal	Halogen
	HATU	O-(7-Azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
15		hexafluorophosphate
	MeOH	Methanol
	min	Minutes
	Ms	Mesyl
20	PdCl ₂ (dppf)	[1,1'-bis(Diphenylphosphino)ferrocene]dichloropalladium (II) complex with
		dichloromethane (1:1)
	Rt	Retention Time
	SPE	Solid phase extraction
	THF	Tetrahydrofuran

25 BIOLOGICAL EXAMPLES

The activity of compounds of formula (I) as p38 inhibitors may be determined by the following *in vitro* assays:

30 Fluorescence anisotropy kinase binding assay 1

The kinase enzyme, fluorescent ligand and a variable concentration of test compound are incubated together to reach thermodynamic equilibrium under conditions such that in the absence of test compound the fluorescent ligand is significantly (>50%) enzyme bound and in the presence of a sufficient concentration (>10x K_i) of a potent inhibitor the anisotropy of
 35 the unbound fluorescent ligand is measurably different from the bound value.

The concentration of kinase enzyme should preferably be $\geq 1 \times K_i$. The concentration of fluorescent ligand required will depend on the instrumentation used, and the fluorescent and physicochemical properties. The concentration used must be lower than the concentration of kinase enzyme, and preferably less than half the kinase enzyme
 40 concentration. A typical protocol is:

All components dissolved in Buffer of final composition 62.5 mM HEPES, pH 7.5, 1.25 mM CHAPS, 1.25 mM DTT, 12.5 mM MgCl₂ 3.3% DMSO.

p38 Enzyme concentration: 12 nM

Fluorescent ligand concentration: 5 nM

Test compound concentration: 0.1 nM - 100 μ M


Components incubated in 30 μ l final volume in NUNC 384 well black microtitre plate
until equilibrium reached (5-30 mins)

Fluorescence anisotropy read in LJJL Acquest.

Definitions: K_i = dissociation constant for inhibitor binding

K_f = dissociation constant for fluorescent ligand binding

The fluorescent ligand is the following compound:




which is derived from 5-[2-(4-aminomethylphenyl)-5-pyridin-4-yl-1H-imidazol-4-yl]-2-chlorophenol and rhodamine green.

Fluorescence anisotropy kinase binding assay 2 (macro volume assay)

The kinase enzyme, fluorescent ligand and a variable concentration of test compound are incubated together to reach thermodynamic equilibrium under conditions such that in the absence of test compound the fluorescent ligand is significantly (>50%) enzyme bound and in the presence of a sufficient concentration (>10 x K_i) of a potent inhibitor the anisotropy of the unbound fluorescent ligand is measurably different from the bound value.

The concentration of kinase enzyme should preferably be 2 x K_f . The concentration of fluorescent ligand required will depend on the instrumentation used, and the fluorescent and physicochemical properties. The concentration used must be lower than the concentration of kinase enzyme, and preferably less than half the kinase enzyme concentration.

The fluorescent ligand is the following compound:



which is derived from 5-[2-(4-aminomethylphenyl)-5-pyridin-4-yl-1H-imidazol-4-yl]-2-chlorophenol and rhodamine green.

Recombinant human p38 α was expressed as a GST-tagged protein. To activate this protein, 3.5 μ M unactivated p38 α was incubated in 50 mM Tris-HCl pH 7.5, 0.1 mM EGTA, 0.1% 2-mercaptoethanol, 0.1mM sodium vanadate, 10mM MgAc, 0.1mM ATP with 200nM MBP-MKK6 DD at 30 degrees for 30 mins. Following activation p38 α was re-purified and the activity assessed using a standard filter-binding assay.

Protocol: All components are dissolved in buffer of composition 62.5 mM HEPES, pH 7.5, 1.25 mM CHAPS, 1 mM DTT, 12.5 mM MgCl₂ with final concentrations of 12nM p38 α and 5nM fluorescent ligand. 30 μ l of this reaction mixture is added to wells containing 1 μ l of various concentrations of test compound (0.28 nM - 16.6 μ M final) or DMSO vehicle (3% final) in NUNC 384 well black microtitre plate and equilibrated for 30-60 mins at room temperature. Fluorescence anisotropy is read in Molecular Devices Acquest (excitation 485nm/emission 535nm).


- Definitions: K_i = dissociation constant for inhibitor binding
 K_f = dissociation constant for fluorescent ligand binding

Fluorescence anisotropy kinase binding assay 3 (micro volume assay)

- The kinase enzyme, fluorescent ligand and a variable concentration of test compound are incubated together to reach thermodynamic equilibrium under conditions such that in the absence of test compound the fluorescent ligand is significantly (>50%) enzyme bound and in the presence of a sufficient concentration (>10 x K_i) of a potent inhibitor the anisotropy of the unbound fluorescent ligand is measurably different from the bound value.

- The concentration of kinase enzyme should preferably be 2 x K_f . The concentration of fluorescent ligand required will depend on the instrumentation used, and the fluorescent and physicochemical properties. The concentration used must be lower than the concentration of kinase enzyme, and preferably less than half the kinase enzyme concentration.

The fluorescent ligand is the following compound:



which is derived from 5-[2-(4-aminomethylphenyl)-5-pyridin-4-yl-1H-imidazol-4-yl]-2-chlorophenol and rhodamine green.

Recombinant human p38 α was expressed as a GST-tagged protein. To activate this protein, 3.5 μ M unactivated p38 α was incubated in 50 mM Tris-HCl pH 7.5, 0.1 mM EGTA, 0.1% 2-

mercaptoethanol, 0.1mM sodium vanadate, 10mM MgAc, 0.1mM ATP with 200nM MBP-MKK6 DD at 30 degrees for 30 mins. Following activation p38 α was re-purified and the activity assessed using a standard filter-binding assay.

- 5 Protocol: All components are dissolved in buffer of composition 62.5 mM HEPES, pH 7.5, 1.25 mM CHAPS, 1 mM DTT, 12.5 mM MgCl₂ with final concentrations of 12nM p38 α and 5nM fluorescent ligand. 6 μ l of this reaction mixture is added to wells containing 0.2 μ l of various concentrations of test compound (0.28 nM - 16.6 μ M final) or DMSO vehicle (3% final) in Greiner 384 well black low volume microtitre plate and equilibrated for 30-60 mins at
- 10 room temperature. Fluorescence anisotropy is read in Molecular Devices Acquest (excitation 485nm/emission 535nm).

Definitions: K_i = dissociation constant for inhibitor binding
 K_f = dissociation constant for fluorescent ligand binding


15

Results

The compounds described in the Examples were tested in at least one of the assays described above and had either IC₅₀ values of <10 μ M or pK_i values of >6.

CLAIMS

1. A compound of formula (I):



(I)

wherein

A is a fused 5-membered heteroaryl ring substituted by $-(CH_2)_m$ heterocyclyl wherein the heterocyclyl is a 5- or 6-membered heterocyclic ring containing one or two heteroatoms independently selected from oxygen, sulfur and nitrogen optionally substituted by up to two substituents independently selected from oxo, C_{1-6} alkyl, $-(CH_2)_n$ phenyl, $-OR^3$, $-(CH_2)_nCO_2R^3$, $-NR^3R^4$ and $-CONR^3R^4$, and

A is optionally further substituted by one substituent selected from $-OR^3$, halogen, trifluoromethyl, $-CN$, $-CO_2R^3$ and C_{1-6} alkyl optionally substituted by hydroxy;

R^1 is selected from methyl and chloro;

R^2 is selected from $-NH-CO-R^5$ and $-CO-NH-(CH_2)_q-R^6$;

R^3 and R^4 are each independently selected from hydrogen and C_{1-6} alkyl;

R^5 is selected from hydrogen, C_{1-6} alkyl, $-(CH_2)_q-C_{3-7}$ cycloalkyl, trifluoromethyl, $-(CH_2)_r$ heteroaryl optionally substituted by R^7 and/or R^8 , and $-(CH_2)_r$ phenyl optionally substituted by R^7 and/or R^8 ;

R^6 is selected from hydrogen, C_{1-6} alkyl, C_{3-7} cycloalkyl, $-CONHR^9$, phenyl optionally substituted by R^7 and/or R^8 , and heteroaryl optionally substituted by R^7 and/or R^8 ;

R^7 is selected from C_{1-6} alkyl, C_{1-6} alkoxy, $-(CH_2)_q-C_{3-7}$ cycloalkyl, $-CONR^9R^{10}$, $-NHCOR^{10}$, halogen, $-CN$, $-(CH_2)_sNR^{11}R^{12}$, trifluoromethyl, phenyl optionally substituted by one or more R^8 groups, and heteroaryl optionally substituted by one or more R^8 groups;

R^8 is selected from C_{1-6} alkyl, C_{1-6} alkoxy, halogen, trifluoromethyl, and $-(CH_2)_sNR^{11}R^{12}$;

R^9 and R^{10} are each independently selected from hydrogen and C_{1-6} alkyl, or

R^9 and R^{10} , together with the nitrogen atom to which they are bound, form a 5- or 6-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N- R^{13} , wherein the ring may be substituted by up to two C_{1-6} alkyl groups;

R¹¹ is selected from hydrogen, C₁₋₆alkyl and -(CH₂)_q-C₃₋₇cycloalkyl optionally substituted by C₁₋₆alkyl.

R¹² is selected from hydrogen and C₁₋₆alkyl, or

- 5 R¹¹ and R¹², together with the nitrogen atom to which they are bound, form a 5- or 6-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N-R¹³;

R¹³ is selected from hydrogen and methyl;

X and Y are each independently selected from hydrogen, methyl and halogen;

m and q are each independently selected from 0, 1 and 2;

- 10 n and r are each independently selected from 0 and 1; and

s is selected from 0, 1, 2 and 3;

with the proviso that:

- 15 A is not substituted by -(CH₂)_mNR¹⁴R¹⁵ wherein R¹⁴ and R¹⁵, together with the nitrogen atom to which they are bound, form a 5- or 6-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulphur and NR¹⁶ wherein R¹⁶ is hydrogen or methyl,

when m is 0, the -(CH₂)_mheterocyclyl group is not a 5- or 6-membered heterocyclyl ring containing nitrogen optionally substituted by C₁₋₂alkyl or -(CH₂)_nCO₂R³, and

- 20 the compound of formula (I) is not 1,1-dimethylethyl 4-(6-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-1,2-benzisoxazol-3-yl)-1-piperazinecarboxylate;

or a pharmaceutically acceptable derivative thereof.

- 25 2. A compound according to claim 1 wherein A is a fused 5-membered heteroaryl ring containing two heteroatoms independently selected from oxygen and nitrogen.

- 30 3. A compound according to claim 1 or claim 2 wherein A is substituted by -(CH₂)_mheterocyclyl wherein the heterocyclyl is a 5- or 6-membered ring containing one or two heteroatoms independently selected from oxygen and nitrogen optionally substituted by up to two substituents independently selected from oxo, C₁₋₆alkyl, -(CH₂)_nphenyl, -OR³, -(CH₂)_nCO₂R³, -NR³R⁴ and -CONR³R⁴.

4. A compound according to any one of the preceding claims wherein R¹ is methyl.

- 35 5. A compound according to any one of the preceding claims wherein R² is -CO-NH-(CH₂)_q-R⁶.

6. A compound according to any one of the preceding claims wherein X is fluorine.

- 40 7. A compound according to claim 1 substantially as hereinbefore defined with reference to any one of Examples 1 to 9, or a pharmaceutically acceptable derivative thereof.

8. A compound selected from:

N-cyclopropyl-3-fluoro-4-methyl-5-[1-(tetrahydro-2*H*-pyran-2-ylmethyl)-1*H*-indazol-5-yl]benzamide;

N-cyclopropyl-3-fluoro-4-methyl-5-[1-(tetrahydro-2-furanylmethyl)-1*H*-indazol-5-yl]benzamide;

and

3-{1-[(4-benzylmorpholin-2-yl)methyl]-1*H*-indazol-5-yl}-*N*-cyclopropyl-5-fluoro-4-methylbenzamide,

or a pharmaceutically acceptable derivative thereof.

9. A pharmaceutical composition comprising at least one compound as claimed in any one of claims 1 to 8, or a pharmaceutically acceptable derivative thereof, in association with one or more pharmaceutically acceptable excipients, diluents and/or carriers.

10. A compound according to any one of claims 1 to 8, or a pharmaceutically acceptable derivative thereof, for use in therapy.


11. A compound as claimed in any one of claims 1 to 8, or a pharmaceutically acceptable derivative thereof, for use in the treatment or prophylaxis of a condition or disease state mediated by p38 kinase activity or mediated by cytokines produced by the activity of p38 kinase.

12. A method for treating a condition or disease state mediated by p38 kinase activity or mediated by cytokines produced by the activity of p38 kinase comprising administering to a patient in need thereof a compound as claimed in any one of claims 1 to 8, or a pharmaceutically acceptable derivative thereof.

13. Use of a compound as claimed in any one of claims 1 to 8, or a pharmaceutically acceptable derivative thereof, in the manufacture of a medicament for use in the treatment of a condition or disease state mediated by p38 kinase activity or mediated by cytokines produced by the activity of p38 kinase.

14. A process for preparing a compound of formula (I) as claimed in any one of claims 1 to 8, or a pharmaceutically acceptable derivative thereof, which comprises:

(a) reacting a compound of formula (II)



(II)

in which R¹, R², X and Y are as defined in claim 1 and A¹ is an unsubstituted fused 5-membered heteroaryl ring,

5 with a halide derivative of formula (III)




(III)

in which $-(CH_2)_m\text{heterocyclyl}$ is as defined in claim 1 and Z is halogen,

10 in the presence of a base;


(b) reacting a compound of formula (IV)



(IV)


15

in which A² is A as defined in claim 1 or a protected form of A or A¹, and Z¹ is halogen, with a compound of formula (VA) or (VB)



20


(VA)



(VB)

- 5 in which R¹, R², X and Y are as defined in claim 1,
in the presence of a catalyst;

(c) reacting a compound of formula (XI)



(XI)

- 10 in which R¹, R², X and Y are as defined in claim 1 and A³ is a fused 5-membered heteroaryl ring substituted by -(CH₂)_mheterocyclyl wherein the heterocyclyl is unsubstituted, with a suitable reagent; or
- 15 (d) final stage modification of one compound of formula (I) as defined in claim 1 to give another compound of formula (I) as defined in claim 1.

INTERNATIONAL SEARCH REPORT

Inte al Application No
PCT/GB2005/000281

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D403/04 C07D405/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, PAJ, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 02/092567 A (LABORATOIRES FOURNIER SA; BARTH, MARTINE; DODEY, PIERRE; PAQUET, JEAN-) 21 November 2002 (2002-11-21) page 4, Formula (I) page 15, line 28 - page 16, line 26 -----	1-14

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

4 May 2005

Date of mailing of the international search report

17/05/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Hoepfner, W

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB2005/000281

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claim 12 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB2005/000281

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 02092567	A	21-11-2002	FR 2824827 A1	22-11-2002
			CA 2447305 A1	21-11-2002
			EP 1387826 A1	11-02-2004
			WO 02092567 A1	21-11-2002
			JP 2004534033 T	11-11-2004
			US 2004138287 A1	15-07-2004
<hr/>				